Famotidine tablets recalled for carton labeling error on strength
Glenmark Therapeutics is recalling famotidine 20 mg tablets after some cartons were labeled with a side label indicating 10 mg instead. The medication inside is correct; only the external carton label is mislabeled.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class II recall for a labeling error where an external side label on the carton incorrectly indicates strength. The product inside is correct; the error is limited to the external packaging label. No reported illnesses or injuries.
Plain-English summary
Glenmark Therapeutics, Inc. is recalling Famotidine Tablets, USP, 20 mg in 200-count bottles distributed nationwide in the United States. Some cartons labeled and containing 20 mg have an external label placed on the side of the carton indicating strength as 10 mg. This external label does not match the actual strength of the product inside.
The recall involves 19,968 bottles of the affected product. The affected cartons bear lot number FA2022001B with an expiration date of March 2025 (NDC 72657-113-20). This is classified as a Class II recall by the U.S. Food and Drug Administration.
The recalled product
- Product
- FAMOTIDINE (FAMOTIDINE)
- Brand
- FAMOTIDINE
- Manufacturer
- Glenmark Therapeutics, Inc.
- Category
- Drug — Over-the-Counter
- Hazard
- strength-labeling-error
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- FA2022001B
- Exp 03/2025
UPCs (3)
- 0372657132015
- 0372657112901
- 0372657113885
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · FAMOTIDINE
- SevereInjectable Famotidine Recalled Due to Microbial Contamination and Endotoxin Testing Failures
FDA (Drugs) · 2025-12-03
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27